Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease

Archives of Neurology

Volumn 69, Issue 12, 2012, Pages 1628-1631

  Kotagal, Vikas ^a   Bohnen, Nicolaas I ^a,b   Müller, Martijn L T M ^a   Koeppe, Robert A ^a   Frey, Kirk A ^a   Albin, Roger L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFARYL)BENZONITRILE C 11; AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; AMYLOID NEUROPATHY; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISTRIBUTION VOLUME; FEMALE; HUMAN; ISOTOPE LABELING; MALE; NEOCORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION;

EID: 84871180084     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.764     Document Type: Article

References (21)

1. Shen F, Smith JA, Chang R, et al. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61(1-2):69-79.
2. Caccamo A, Oddo S, Billings LM, et al.M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671-682. (Pubitemid 43290127)
3. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease: an update. Curr Alzheimer Res. 2007;4(5):577-580. (Pubitemid 350248396)
4. Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci. 2009;29(14):4442-4460.
5. Perry EK, Court JA, Lloyd S, et al. Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe. Ann N Y Acad Sci . 1996;777:388-392. (Pubitemid 26149219)
6. Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108(36):14968-14973.
7. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab. 2008;28(3):441-444. (Pubitemid 351304276)
8. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis . 2010;40(1):216-221.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
10. 11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol. 1997;24(2):197-199.
11. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539. (Pubitemid 47301451)
12. Koeppe RA, Frey KA. Equilibrium analysis of [11C]PIB studies. Neuroimage. 2008; 41(suppl 2):T30. doi:10.1016/j.neuroimage.2008.04.204.
13. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840. (Pubitemid 26292051)
14. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32(2):86-102. (Pubitemid 46597955)
15. Ginovart N,Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab. 2001;21(11):1342- 1353. (Pubitemid 33130946)
16. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium vs compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab. 1997;17(9):919-931. (Pubitemid 27396580)
17. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab. 1999;19(12):1376-1384. (Pubitemid 30013629)
18. Nelson RL, Guo Z, Halagappa VM, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205(1):166-176. (Pubitemid 46617502)
19. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331-1338.
20. Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Gender and the Parkinson's disease phenotype. J Neurol. 2005;252(10):1201-1205. (Pubitemid 41443619)
21. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate vs putamen in Parkinson's disease. Brain. 2008;131(pt 1):120-131.